CY1106131T1 - Θepαπευτικη αγωγη της μασταλγιας με 4-υδροξυ ταμοξιφενη - Google Patents

Θepαπευτικη αγωγη της μασταλγιας με 4-υδροξυ ταμοξιφενη

Info

Publication number
CY1106131T1
CY1106131T1 CY20061101041T CY061101041T CY1106131T1 CY 1106131 T1 CY1106131 T1 CY 1106131T1 CY 20061101041 T CY20061101041 T CY 20061101041T CY 061101041 T CY061101041 T CY 061101041T CY 1106131 T1 CY1106131 T1 CY 1106131T1
Authority
CY
Cyprus
Prior art keywords
mastalgia
hydroxy
tamoxifene
therapeutic induction
therapeutic
Prior art date
Application number
CY20061101041T
Other languages
English (en)
Inventor
Bruno De Lignieres
Original Assignee
Laboratoires Besins International
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Besins International filed Critical Laboratoires Besins International
Publication of CY1106131T1 publication Critical patent/CY1106131T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Abstract

Μέθοδος δια τη θεραπευτική αγωγή που περιλαμβάνει χορήγηση 4-υδρόξυ ταμοξιφένης μέσω της επιδερμίδος σε ασθενή ο οποίος έχει μασταλγία. Η 4-υδρόξυ ταμοξιφένη μπορεί να μετατραπεί σε σκεύασμα εις υδατοαλκοολικό πήγμα ή αλκοολικό διάλυμα.
CY20061101041T 2002-12-18 2006-07-27 Θepαπευτικη αγωγη της μασταλγιας με 4-υδροξυ ταμοξιφενη CY1106131T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43395902P 2002-12-18 2002-12-18
PCT/EP2003/015028 WO2004054557A2 (en) 2002-12-18 2003-12-15 Treatment of mastalgia with 4-hydroxy tamoxifen

Publications (1)

Publication Number Publication Date
CY1106131T1 true CY1106131T1 (el) 2011-06-08

Family

ID=32595255

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061101041T CY1106131T1 (el) 2002-12-18 2006-07-27 Θepαπευτικη αγωγη της μασταλγιας με 4-υδροξυ ταμοξιφενη

Country Status (16)

Country Link
US (1) US7786172B2 (el)
EP (1) EP1572178B1 (el)
JP (1) JP4938237B2 (el)
AT (1) ATE324880T1 (el)
AU (1) AU2003303033B2 (el)
CA (1) CA2509660C (el)
CY (1) CY1106131T1 (el)
DE (1) DE60305068T2 (el)
DK (1) DK1572178T3 (el)
ES (1) ES2263072T3 (el)
HK (1) HK1075403A1 (el)
MX (1) MXPA05006526A (el)
NZ (1) NZ540494A (el)
PT (1) PT1572178E (el)
SI (1) SI1572178T1 (el)
WO (1) WO2004054557A2 (el)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1572171B1 (en) * 2002-12-18 2009-04-22 Laboratoires Besins International Reduction of breast density with 4-hydroxy tamoxifen
EP1952810B1 (en) * 2003-04-01 2014-01-08 Besins Healthcare Luxembourg SARL Treatment of breast cancer with 4-hydroxytamoxifen
WO2004110420A1 (en) * 2003-06-09 2004-12-23 Ascend Therapeutics, Inc. Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen
US7968532B2 (en) * 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
ATE391499T1 (de) * 2004-03-22 2008-04-15 Besins Int Lab 4-hydroxytamoxifen zur behandlung und prophylaxe von benignen brusterkrankungen
EP1579857A1 (en) * 2004-03-22 2005-09-28 Laboratoires Besins International Chemically stable compositions of 4-hydroxy tamoxifen
US7507769B2 (en) 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1579856A1 (en) * 2004-03-22 2005-09-28 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1647271A1 (en) * 2004-10-14 2006-04-19 Laboratoires Besins International 4-Hydroxy tamoxifen gel formulations
EP1799201B1 (en) * 2004-10-14 2008-11-26 Laboratoires Besins International 4-hydroxy tamoxifen gel formulations
JP5544458B2 (ja) * 2005-07-12 2014-07-09 アンピオ ファーマシューティカルズ，インコーポレイテッド 疾病を治療するための医薬製品の製造においてトリロスタンｉｉｉを使用する方法及びトリロスタンｉｉｉを含む医薬製品
SG2014008171A (en) 2009-06-22 2014-04-28 Ampio Pharmaceuticals Inc Method for treatment of diseases
US9351979B2 (en) 2012-12-19 2016-05-31 Ampio Pharmaceuticals, Inc. Methods of treatment of diseases
AU2018329202B2 (en) 2017-09-11 2022-10-27 Atossa Therapeutics, Inc. Methods for making and using endoxifen

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2558373B1 (fr) * 1984-01-20 1987-07-03 Mauvais Jarvis Pierre Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee
DE3781546D1 (de) * 1987-04-21 1992-10-08 Heumann Pharma Gmbh & Co Stabile loesungsmitteladdukte von z-1-(p-beta-dimethylamino-ethoxyphenyl)-1-(p-hydroxyphenyl)-2-phenylbut-1-en.
US5045553A (en) * 1987-06-24 1991-09-03 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutical composition for percutaneous drug absorption and percutaneous drug absorption promoter
DE3836862A1 (de) 1988-10-27 1990-05-03 Schering Ag Mittel zur transdermalen applikation von steroidhormonen
US5189212A (en) * 1990-09-07 1993-02-23 University Of Georgia Research Foundation, Inc. Triarylethylene carboxylic acids with estrogenic activity
TW218849B (el) 1991-05-17 1994-01-11 Bristol Myers Squibb Co
US5613958A (en) * 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
US5720963A (en) * 1994-08-26 1998-02-24 Mary Kay Inc. Barrier disruption treatments for structurally deteriorated skin
IL120266A (en) * 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
IL120268A0 (en) * 1996-02-28 1997-06-10 Pfizer Use of (E)-1-[4'-(2-alkylaminoethioxy)phenyl]1-(3'-hydroxyphenyl)-2-phenylbut-1-enes in inhibiting pathological conditions
US6548491B2 (en) * 1997-12-24 2003-04-15 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
US6013270A (en) * 1998-04-20 2000-01-11 The Procter & Gamble Company Skin care kit
ES2239057T3 (es) * 1999-12-16 2005-09-16 Dermatrends, Inc. Agentes de liberacion de hidroxido utilizados como potenciadores de la permeacion cutanea.
DE10033853A1 (de) * 2000-07-12 2002-01-31 Hexal Ag Transdermales therapeutisches System mit hochdispersem Siliziumdioxid
EP1177787A3 (en) 2000-07-28 2003-09-10 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating cataracts
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
DE10054294A1 (de) * 2000-11-02 2002-05-16 Heinrich Wieland Topische Behandlung bei der Mastalgie
ES2233570T3 (es) * 2000-11-30 2005-06-16 Pfizer Products Inc. Composicion que contiene agonistas/antagosnistas de estrogenos y testosterona para tratar un descenso en el nivel de la hormona testosterona.
WO2003011282A1 (en) * 2001-07-31 2003-02-13 Pfizer Products Inc. Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins
ES2330188T3 (es) * 2001-12-07 2009-12-07 Besins Manufacturing Belgium Composicion farmaceutica en forma de gel o de solucion a base de dihidrotestoterona, su procedimiento de preparacion y sus utilizaciones.
EP1572171B1 (en) * 2002-12-18 2009-04-22 Laboratoires Besins International Reduction of breast density with 4-hydroxy tamoxifen
EP1952810B1 (en) * 2003-04-01 2014-01-08 Besins Healthcare Luxembourg SARL Treatment of breast cancer with 4-hydroxytamoxifen
WO2004110420A1 (en) * 2003-06-09 2004-12-23 Ascend Therapeutics, Inc. Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen
US7968532B2 (en) * 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
US7507769B2 (en) * 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1579856A1 (en) 2004-03-22 2005-09-28 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1579857A1 (en) 2004-03-22 2005-09-28 Laboratoires Besins International Chemically stable compositions of 4-hydroxy tamoxifen
EP1647271A1 (en) * 2004-10-14 2006-04-19 Laboratoires Besins International 4-Hydroxy tamoxifen gel formulations

Also Published As

Publication number Publication date
ATE324880T1 (de) 2006-06-15
AU2003303033B2 (en) 2009-06-04
PT1572178E (pt) 2006-09-29
ES2263072T3 (es) 2006-12-01
CA2509660A1 (en) 2004-07-01
EP1572178B1 (en) 2006-05-03
JP2006514949A (ja) 2006-05-18
WO2004054557A2 (en) 2004-07-01
MXPA05006526A (es) 2006-02-17
US7786172B2 (en) 2010-08-31
DK1572178T3 (da) 2006-09-11
WO2004054557A3 (en) 2004-08-05
HK1075403A1 (en) 2005-12-16
CA2509660C (en) 2011-08-30
NZ540494A (en) 2007-05-31
DE60305068T2 (de) 2007-01-11
JP4938237B2 (ja) 2012-05-23
US20050032909A1 (en) 2005-02-10
DE60305068D1 (de) 2006-06-08
SI1572178T1 (sl) 2006-10-31
EP1572178A2 (en) 2005-09-14
AU2003303033A1 (en) 2004-07-09

Similar Documents

Publication Publication Date Title
CY1106131T1 (el) Θepαπευτικη αγωγη της μασταλγιας με 4-υδροξυ ταμοξιφενη
CY1124144T1 (el) Συνθεσεις και μεθοδοι για θεραπεια εγκεφαλικου επεισοδιου σε ενα υποκειμενο επι ταυτοχρονης θεραπειας στατινης
CY1123052T1 (el) Συνθεσεις και μεθοδοι σχετικες με παραλλαγες της πρωτεϊνες α (spa)
CY1123255T1 (el) Σχημα δοσολογιας για εναν αγωνιστη υποδοχεα s1p
CY1121041T1 (el) Μεθοδοι αγωγης παιδιατρικων ασθενων με τη χρηση δεξμεδετομιδινης
CY1117963T1 (el) Αντισωματα που προσδενουν τα il-17a και il-17f
CY1115690T1 (el) Συνθεσεις βασιζομενες σε arthrospirα και χρησεις αυτων
CY1116494T1 (el) Θεραπευτικη αγωγη θρομβοεμβολικων διαταραχων με ριβαροξαβανη
CY1110889T1 (el) C-αρυλο γλυκοζιτικοι sglt2 αναστολεις και μεθοδος για την παραγωγη τους
CY1108436T1 (el) Χορηγηση καψαϊκινοειδων
EA201991556A1 (ru) Ингибиторы фосфодиэстеразы и способы лечения микробной инфекции
CY1115745T1 (el) Συνθεσεις και μεθοδοι για αντιμετωπιση ή προληψη σχετιζομενης με οξαλικα νοσου
EA201100335A8 (ru) Производные пурина для применения при лечении связанных с fab заболеваний
CY1117584T1 (el) Παραγωγα 1-βενζυλ-3-υδροξυμεθυλινδαζολης και η χρηση τους στη θεραπευτικη αντιμετωπιση νοσων που βασιζονται στην εκφραση των mcp-1, cx3cr1
EA200500859A1 (ru) Хинолинилпирролопиразолы
EA200801427A1 (ru) Молекулы антитела со специфической активностью в отношении интерлейкина-6 (ил-6) человека
DE602007004514D1 (de) Prä-exzitations-pacing zur behandlung von hypertonie
EA200901211A1 (ru) Антигены белка с5 и их применение
PT933993E (pt) Compostos de ciclopentano substituidos, uteis como inibidores de neuraminidase
CY1117504T1 (el) Παραγωγα 1-βενζυλ-3-υδροξυμεθυλινδαζολης και η χρηση τους στη θεραπευτικη αντιμετωπιση νοσων που βασιζονται στην εκφραση των mcp-1, και cx3cr1
CY1112058T1 (el) Χρηση των χιτοζανων για την αυξηση του βαθμου αναπτυξης των νυχιων
CY1106026T1 (el) Αρυλσουλφοναμιδια ως ανταγωνιστες της σepοτονινης για την αγωγη της παχυσαρκιας
EA200602180A1 (ru) Производные 2-(1h-индолилсульфанил)ариламина для применения при лечении аффективных расстройств, боли, нгдв и стрессового недержания мочи
ATE442861T1 (de) Gegen antikörper gerichtete photodynamische therapie
NO20044448L (no) Nye forbindelser